The Forecast Just Changed on Stealth BioTherapeutics Corp (NASDAQ:MITO)

The Forecast Just Changed on Stealth BioTherapeutics Corp (NASDAQ:MITO)

SHARE

The Stealth BioTherapeutics Corp (MITO) shares are trading at higher $2.04 and the avg recommendation for the stock is Moderate Buy.

To add more color to this target, the company’s high over the last year is $14.41 and the low is $0.90. Over the last 52 weeks, MITO is down -85.84% while the S&P 500 is up 1.07%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, MITO reported a profit of $0.64 million. Stealth BioTherapeutics Corp also saw revenues increase to $15.03 million. In addition, MITO has free cash flow of $0.0 as of 03-2020 The company’s EBITDA came in at -$15.03 million which compares well with its peers.

MITO Return on Equity (ROE) is -413.30%, and its Return on Assets is -98.10%. All told, it is clear that, MITO needs to be on your watchlist.

Find out when MITO reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. MITO has a short ratio of 0.10 and outstanding shares of 36.39M.

Company Outlook

MITO has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 58810.0 and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -1.26. Stealth BioTherapeutics Corp MITO also noted assets of $32.15 million at the end of the last quarter. Investors should also keep an eye on sector updates as MITO has historically followed its peers on positive news.

All told, Stealth BioTherapeutics Corp MITO has strung together solid data and demonstrated underlying fundamentals. At its current valuation, MITO represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Stealth BioTherapeutics Corp MITO is now commanding a market cap of 70.22M and a float of 5.73M. MITO is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of MITO stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in MITO, either long or short, and we have not been compensated for this article.